middle.news
Immuron’s FY25 Sales Surge 49% as ProIBS Launch and FDA Milestones Loom
4:04am on Saturday 30th of August, 2025 AEST
•
Biotechnology
Read Story
Immuron’s FY25 Sales Surge 49% as ProIBS Launch and FDA Milestones Loom
4:04am on Saturday 30th of August, 2025 AEST
Key Points
FY25 global sales revenue up 49% to A$7.3 million
North American Travelan® sales surged 76%
ProIBS product launch planned for Q1 2026 in Australia
Key clinical milestones – Travelan® FDA meeting and IMM-529 IND submission/approval
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Immuron (ASX:IMC)
OPEN ARTICLE